Table 4.

Dosing, mutation status and virology

Seq #	Dose Level	Diagnosis	# Rx	BR	Mutation Status				NA	Viral shedding
					Ras (codon)			Braf (codon)		Serum	Saliva	Urine	Feces
					12	13	61	600
101	1	Ovarian	1	SD	WT	WT	WT	WT	D8	N	N	N	N
102	1	Colon	1	PD	WT	WT	WT	WT	D8	N	N	N	N
103	1	Leio*	1	SD	WT	WT	WT	WT	D8	N	N	N	N
201	2	Colon	1	PD	G>V	WT	WT	WT	D8	N	N	N	N
202	2	Ovarian	3	SD	WT	WT	WT	WT	D8	N	N	N	N
203	2	Carcinoid	1	SD	ND	ND	ND	ND	D8	D1	D3	D3	N
301	3	Cervical	1	PD	WT	WT	WT	WT	D5	N	N	N	N
302	3	Ovarian	1	SD	WT	WT	WT	WT	D5	D3	N	D3	N
303	3	Prostate	1	PD	G>A	WT	WT	WT	D28	N	N	N	N
401	4	Ovarian	1	PD	WT	WT	WT	WT	D5	N	N	N	N
402	4	Colon	1	PD	WT	WT	WT	WT	D5	N	N	N	N
403	4	Cervical	1	PD	WT	WT	WT	WT	D8	N	N	N	N
501	5	Breast	7	PR	G>A	WT	WT	WT	D14	N	D149	N	D64
502	5	Breast	1	PD	G>A	WT	WT	V>E	D8	N	N	N	N
503	5	Lung	1	PD	WT	WT	WT	WT	D8	D21	N	D8	N
601	6	Colon	1	PD	WT	WT	WT	WT	D8	N	N	D14	N
602	6	Ovarian	1	SD	WT	WT	WT	WT	D8	N	N	N	N
603	6	Ovarian	2	SD	G>V	WT	WT	WT	D1	D1	D1	D1	D8

Abbreviations: Leio* leiomyosarcoma, # Rx number of doses, BR best response, SD stable disease, PD progressive disease, PR partial response, NA neutralizing antibody, N not detected, D earliest day of detection, ND not done, WT wild type, G>V glycine>valine (mutation), G>A glycine >alanine (mutation), V>E valine>glutamic acid (mutation)